Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

Brian Feagan; William Sandborn; Bosny Pierre-Louis; Christopher Fourment; Maria Abreu

doi:10.1097/01.MIB.0000442971.65229.5b

Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

Brian Feagan, William Sandborn, Bosny Pierre-Louis, Christopher Fourment, Maria Abreu

Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	E7
Journal	Inflammatory bowel diseases
Volume	20
Issue number	2
DOIs	https://doi.org/10.1097/01.MIB.0000442971.65229.5b
State	Published - Feb 2014

ASJC Scopus subject areas

Immunology and Allergy
Gastroenterology

Access to Document

10.1097/01.MIB.0000442971.65229.5b

Cite this

Feagan, B., Sandborn, W., Pierre-Louis, B., Fourment, C., & Abreu, M. (2014). Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82)). Inflammatory bowel diseases, 20(2), E7. https://doi.org/10.1097/01.MIB.0000442971.65229.5b

Erratum : P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82)). / Feagan, Brian; Sandborn, William; Pierre-Louis, Bosny; Fourment, Christopher; Abreu, Maria.

In: Inflammatory bowel diseases, Vol. 20, No. 2, 02.2014, p. E7.

Research output: Contribution to journal › Comment/debate › peer-review

Feagan, B, Sandborn, W, Pierre-Louis, B, Fourment, C & Abreu, M 2014, 'Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))', Inflammatory bowel diseases, vol. 20, no. 2, pp. E7. https://doi.org/10.1097/01.MIB.0000442971.65229.5b

Feagan B, Sandborn W, Pierre-Louis B, Fourment C, Abreu M. Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82)). Inflammatory bowel diseases. 2014 Feb;20(2):E7. https://doi.org/10.1097/01.MIB.0000442971.65229.5b

Feagan, Brian ; Sandborn, William ; Pierre-Louis, Bosny ; Fourment, Christopher ; Abreu, Maria. / Erratum : P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82)). In: Inflammatory bowel diseases. 2014 ; Vol. 20, No. 2. pp. E7.

@article{4ca88cf359b64f3cad256b93d93be059,

title = "Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))",

author = "Brian Feagan and William Sandborn and Bosny Pierre-Louis and Christopher Fourment and Maria Abreu",

year = "2014",

month = feb,

doi = "10.1097/01.MIB.0000442971.65229.5b",

language = "English (US)",

volume = "20",

pages = "E7",

journal = "Inflammatory Bowel Diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Erratum

T2 - P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

AU - Feagan, Brian

AU - Sandborn, William

AU - Pierre-Louis, Bosny

AU - Fourment, Christopher

AU - Abreu, Maria

PY - 2014/2

Y1 - 2014/2

UR - http://www.scopus.com/inward/record.url?scp=84893737768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893737768&partnerID=8YFLogxK

U2 - 10.1097/01.MIB.0000442971.65229.5b

DO - 10.1097/01.MIB.0000442971.65229.5b

M3 - Comment/debate

AN - SCOPUS:84893737768

VL - 20

SP - E7

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -

Erratum: P-145 WELCOME 54-week open-label extension: Efficacy of certolizumab pegol in Crohn's disease patients with secondary failure and anti-infliximab antibodies (Inflammatory Bowel Diseases (2013) 19 (S82))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this